Cardio-Oncology: An Ongoing Evolution

Petek, Bradley J.; Greenman, Chris; Herrmann, Joerg; Ewer, Michael S.; Jones, Robin L.

doi:10.2217/fon.15.89

Cited by 12 publications

(11 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cause of death analysis also identifies the large group of cancer survivor populations who never have primary cancer as the leading cause of death, and could have these risks addressed by their primary care physician in shared care, and/or specialists such as cardiologists, oncocardiologists, and others to address their comorbidities and treatment-related effects. 12 Risk clusters 3, 4, 5, and 6 all had high-risk periods longer than 5 years, the highest mortality gap percentage in the stable period, and had primary and secondary cancers contribute to the majority of observed deaths; this argues that they would benefit most from greater oncology involvement. Cluster 1 had the lowest high-risk period duration and median mortality gap, and had cardiac and other causes contributing to a majority of deaths.…”

Section: Discussionmentioning

confidence: 99%

Defining Survivorship Trajectories Across Patients With Solid Tumors

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Defining Survivorship Trajectories Across Patients With Solid Tumors

et al. 2018

View full text Add to dashboard Cite

show abstract

“…El volumen de pacientes sometidos a terapias oncológicas con resultado exitoso se ha incrementado dramáticamente en las últimas décadas 7 ; por ejemplo, en linfomas, la sobrevida ha experimentado un aumento desde 47% en 1979 a 70% en 2010 (Tabla 1) 8 . La mayor sobrevida de los enfermos ha hecho evidente la aparición de eventos cardiovasculares en el seguimiento y de efectos adversos a las drogas oncológicas 9 .…”

Section: Terapias Oncológicas Y Cardiotoxicidadunclassified

Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología

et al. 2018

View full text Add to dashboard Cite

Recently, we have witnessed major improvements in cancer treatment. Early diagnosis and development of new therapies have reduced cancer-related mortality. However, these new therapies, along with greater patient survival, are associated with an increase in untoward effects, particularly in the cardiovascular system. Although cardiotoxicity induced by oncologic treatments affects predominantly the myocardium, it can also involve other structures of the cardiovascular system, becoming one of the main causes of morbidity and mortality in those who survive cancer. The main objective of cardio-oncology is to achieve the maximum benefits of oncologic treatments while minimizing their deleterious cardiovascular effects. It harbors the stratification of patients at risk of cardiotoxicity, the implementation of diagnostic tools (imaging techniques and biomarkers) for early diagnosis, preventive strategies and early treatment options for the complications. Herein, we discuss the basic knowledge for the implementation of cardio-oncology units and their role in the management of cancer patients, the diagnostic tools available to detect cardiotoxicity and the present therapeutic options.

show abstract

“…The rapid development of novel cancer therapies will continue to generate questions of cardiac risk and cardiac protection in cancer patients over time. Cancer survival has been greatly impacted upon by the development of modern cancer treatments and cardio-oncology is a field in rapid evolution [52]. Recent echocardiographic noninvasive techniques are expected to provide large clinical implications in acute and chronic cancer patients.…”

Section: Strain In Cardio-oncologymentioning

confidence: 99%

Clinical Application of 2D Speckle Tracking Strain for Assessing Cardio-Toxicity in Oncology

Stefani¹,

Pedrizzetti

Galanti³

2016

JFMK

View full text Add to dashboard Cite

Echocardiography has recently undergone innovations due to the availability of deformation parameters as strain, strain rate, torsion and rotation that allow an accurate assessment of myocardial function. Because of this general progress, the importance of myocardial deformation parameters has been highlighted, and some aspects of their clinical and research applications have recently been considered for the daily management of many acute and chronic metabolic diseases. The deformation parameters are largely proposed for the early detection of myocardial dysfunction, especially in the case of patients being completely asymptomatic. Strain analysis is extensively applied to cardiomyopathies, to coronary artery disease, or to the evaluation of the "forgotten chambers", such as the right ventricles and atria. More recently, several other clinical contexts, like non-communicable chronic diseases (NCCD), have actually been benefitting from specific evaluation by strain analysis. Lately, some specific aspects of strain evaluation, particularly Global Longitudinal Strain (GLS) have been shown to provide useful information of clinical relevance in the case of cancer patients. This paper presents an initial review of the recent applications of strain analysis in cardio-oncology, in order to share the recent experience in this field and to support the role of these parameters in cardio-oncology.

show abstract

Cardio-Oncology: An Ongoing Evolution

Cited by 12 publications

References 50 publications

Defining Survivorship Trajectories Across Patients With Solid Tumors

Defining Survivorship Trajectories Across Patients With Solid Tumors

Cardiotoxicidad inducida por tratamientos oncológicos. Fundamentos para la implementación de equipos de Cardio-Oncología

Clinical Application of 2D Speckle Tracking Strain for Assessing Cardio-Toxicity in Oncology

Contact Info

Product

Resources

About